New Diabetic Macular Edema Implant Shows Potential
The EC-104 implant showed safety and efficacy in patients who previously had a suboptimal response to standard eye treatments.
Updated on Oct. 21, 2026 in Diabetes
Live Poll
Do you feel that new medical treatments are making managing chronic health conditions easier?
A Phase 2 clinical trial for the EC-104 fluocinolone acetonide implant has met its primary safety endpoints in patients with diabetic macular edema. The treatment, intended for those who previously responded poorly to anti-VEGF therapy, also showed improved anatomical outcomes over 24 weeks.
Why it matters
Managing diabetic macular edema remains challenging for patients who do not respond well to standard anti-VEGF injections. This trial offers a potential alternative treatment path by evaluating a sustained-release implant that may simplify long-term management for these individuals.
In a Phase 2 randomized trial, the EC-104 fluocinolone acetonide implant was compared against a dexamethasone intravitreal implant in patients with diabetic macular edema. The study confirmed the safety profile of both 0.14 mg and 0.092 mg doses, with results measured over 24 weeks.
The players
Eclipse Life Sciences
A biotechnology company currently developing the EC-104 fluocinolone acetonide implant for retinal conditions.
The details
The EC-104 is an extended-release intravitreal implant designed to deliver medication directly into the eye. By continuously releasing fluocinolone acetonide, the implant aims to reduce central subfield thickness and improve visual acuity, particularly in patients who have failed to achieve adequate results with anti-VEGF therapies. The trial confirmed that the device maintained these anatomical improvements over the study period with low rates of adverse events.
Timeline
24 weeks: Duration of the study measuring secondary endpoints and anatomical improvements.
Health Landscape
This development marks a continued progression in retinal care toward sustained-release technologies for chronic conditions. It builds upon the established industry trend of exploring durable, long-acting intraocular delivery systems to manage diabetic eye disease.
Patients currently struggling with suboptimal responses to standard anti-VEGF injections for diabetic macular edema may want to monitor reports on this emerging technology. Discuss the potential for future long-acting implants with your ophthalmologist to understand how they might fit into your long-term eye care plan.
The takeaway
The EC-104 implant shows promise as a potential new therapy for those whose diabetic macular edema has not responded to traditional treatments. Patients should continue regular retinal screenings and discuss any ongoing vision changes with their eye care specialist.
Further reading
For more information on current treatment standards, visit Diabetes.
Source note: This article includes information reported by Healio.
Live Poll
Do you feel that new medical treatments are making managing chronic health conditions easier?
